Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Debt (2017 - 2024)

United Therapeutics' Non-Current Debt history spans 13 years, with the latest figure at $100.0 million for Q2 2024.

  • On a quarterly basis, Non-Current Debt fell 87.5% to $100.0 million in Q2 2024 year-over-year; TTM through Jun 2024 was $100.0 million, a 87.5% decrease, with the full-year FY2023 number at $300.0 million, down 62.5% from a year prior.
  • Non-Current Debt hit $100.0 million in Q2 2024 for United Therapeutics, down from $200.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for UTHR hit a ceiling of $800.0 million in Q1 2020 and a floor of $100.0 million in Q2 2024.
  • Historically, Non-Current Debt has averaged $683.3 million across 5 years, with a median of $800.0 million in 2020.
  • Biggest five-year swings in Non-Current Debt: soared 33.33% in 2020 and later tumbled 87.5% in 2024.
  • Tracing UTHR's Non-Current Debt over 5 years: stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then plummeted by 62.5% to $300.0 million in 2023, then crashed by 66.67% to $100.0 million in 2024.
  • Business Quant data shows Non-Current Debt for UTHR at $100.0 million in Q2 2024, $200.0 million in Q1 2024, and $300.0 million in Q4 2023.